I’ve completed the final curation pass and delivered the requested Immune‑oncology 1000‑gene panel for human TME, with full annotations, coverage summaries, comparison figures, and validation UMAPs in your workdir.

Key outputs (paths relative to your workdir)
- Curated tables
  - selection_expert/curated/final_panel_1000.csv
    Columns: gene_symbol, ensembl_id, category_major, category_minor, methods_present, aggregate_rank, aggregate_score, bio_relevance_score_0to5, rationale_short, spatial_suitability, pct_expr, mean_expr, gini_proxy
  - selection_expert/curated/final_panel_1000_grouped.tsv
  - selection_expert/curated/tables/method_panels_presence.csv
- Coverage and notes
  - selection_expert/curated/final_panel_coverage_summary.md
  - selection_expert/curated/notes_curation.md
- Figures
  - selection_expert/curated/figures/venn_methods.png (DE vs scGeneFit vs RF)
  - selection_expert/curated/figures/upset_methods.png (all 5 methods; copied)
  - selection_expert/curated/figures/umap_finalpanel_Immune_broad.png
  - selection_expert/curated/figures/umap_finalpanel_cell_type.png
  - selection_expert/curated/figures/umap_finalpanel_Malignant_vs_Other.png
  - selection_expert/curated/figures/confusion_cell_type_rf_finalpanel.png
- Report
  - selection_expert/report_analysis_expert_curation_final.md
- Reproducible notebook for curation
  - selection_expert/03b_curation_execute.ipynb

What I did (high level)
- Used the active dataset: selection_expert/adata_downsampled_50k_3kHVG.h5ad.
- Started from your aggregate top ranking (aggregate/aggregate_ranking_scores.csv) and method results (HVG stability, DE Immune, DE Malignant vs Other, SpaPROS, scGeneFit, Random Forest).
- Built a candidate pool (~1500 genes) from the aggregate ranking and tracked per-method presence.
- Computed expression robustness from adata.var: pct_expr = 100%−dropout, mean_expr = mean_counts, and standardized variance (vst) as gini_proxy.
- Biological relevance score (0–5) combined: expression robustness (scaled), method consensus (methods_count + aggregate_score), and curated TME biology boosts (lineage markers, cytokines/chemokines/recep/checkpoints, oncogenic pathway nodes, cell cycle/DDR/stress, hypoxia/EMT/ECM/vasculature). Applied spatial heuristics (ribosomal/mitochondrial/KRTAP family blacklist; category‑adj thresholds for detectability; allow critical checkpoint markers).
- Enforced panel composition (approximate targets): Immune lineage/state ~400; Cytokines/Chemokines/Checkpoints ~200; Cancer pathways ~200; CellCycle/DDR/Stress ~120; Hypoxia/Angio/EMT/ECM/Vasc ~80.
- Ensured coverage of requested IO axes and HLA breadth. Verified presence of key lineage and exhaustion/activation markers; backfilled three missing required genes (ANGPT2, COL3A1, SNAI2) while maintaining panel size = 1000.
- Produced per-gene annotations, method presence table, UMAPs using only the final 1000‑gene panel, a quick RF confusion matrix for cell_type, and the method intersection figures.

Panel coverage and composition
- The coverage summary (curated/final_panel_coverage_summary.md) lists major category counts and explicitly enumerates all required IO and oncology pathway highlights included in the final panel: T cell core (CD3D/E, TRAC, CD4, CD8A/B), Treg (FOXP3, IL2RA), Tfh (BCL6, ICOS), Th1/Th2/Th17 (TBX21, GATA3, RORC), NK/cytotoxic (NKG7, KLRD1, GZMB, PRF1, IFNG), B/plasma (MS4A1, CD79A/B, SDC1, PRDM1, IRF4, XBP1, MZB1), DCs (ITGAX, CLEC9A, LAMP3), mono/macrophage (LST1, FCGR3A, ITGAM, CSF1R, MRC1, MARCO), neutrophil/MDSC (S100A8/A9, FCGR3B); checkpoints/exhaustion (PDCD1, CTLA4, LAG3, HAVCR2, TIGIT, TOX, BATF, CXCL13), activation (CD69, CD40LG), HLA class I and class II; malignant vs non‑malignant discrimination (EPCAM, KRTs, MUC1, PTPRC), RTKs (EGFR, ERBB2/3), RAS/RAF/MEK (KRAS, BRAF, MAPK1/3), PI3K/PTEN/AKT/MTOR, JAK/STAT, TGF‑β/SMAD, WNT/FZD/CTNNB1, cell cycle/DDR/stress, and hypoxia/angiogenesis/EMT/ECM/vasculature (HIF1A, VEGFA, KDR, FLT1, ANGPT2, VWF, VIM, FN1, SNAI, TWIST, COLs, PDGFRA/B, PECAM1, EMCN).

Method intersections and metrics
- Venn diagram comparing DE vs scGeneFit vs Random Forest (curated/figures/venn_methods.png).
- UpSet plot for all 5 methods (copied to curated/figures/upset_methods.png).
- UMAP evaluation using only the final 1000 genes:
  - curated/figures/umap_finalpanel_cell_type.png
  - curated/figures/umap_finalpanel_Immune_broad.png
  - curated/figures/umap_finalpanel_Malignant_vs_Other.png
- RF confusion matrix (cell_type) using only the final panel:
  - curated/figures/confusion_cell_type_rf_finalpanel.png

Notes on spatial suitability
- Blacklisted RPL/RPS/MT-/KRTAP/LOC families to minimize probe off-target risk.
- Relaxed detectability thresholds for critical cytokines/checkpoints and HLA members while maintaining robust detection for the bulk of panel genes.
- The per-gene column spatial_suitability indicates heuristic suitability (Yes/No).

Executive summary (for biologist/reporter)
We curated a 1000-gene immune-oncology panel optimized for human TME spatial profiling by integrating multi-method rankings (HVG, DE, SpaPROS, scGeneFit, Random Forest), dataset expression robustness, and curated IO/oncology pathway knowledge. The final panel ensures comprehensive coverage across immune lineages (T, B, NK, myeloid, DC, neutrophil/MDSC), checkpoint/exhaustion and activation pathways, antigen presentation (HLA I/II), malignant vs non-malignant distinction (EPCAM/KRT/MUC1 vs PTPRC), and core cancer signaling axes (RTK/MAPK/PI3K/JAK-STAT/TGF-β/WNT/Notch) alongside cell cycle/DDR/stress and hypoxia/angiogenesis/EMT/ECM/vasculature. We include per-gene scoring and annotations for downstream QC and probe design, method intersection figures, and UMAPs using only the curated panel. All outputs are under selection_expert/curated; the main table is curated/final_panel_1000.csv.

Next steps
- Optional: refine probe lists against platform-specific probe design constraints (e.g., low-complexity regions, GC content, off-target BLAST).
- Optional: add pathway enrichments, and export gene lists in platform-ready formats.